by mariel | Dec 22, 2025 | Portfolio News
Viridian submitted its BLA in TED and subsequently announced the BLA received Priority Review with a PDUFA target action date of June 30, 2026. by mariel | Dec 22, 2025 | Portfolio News
Assembly reported positive interim Phase 1b HSV data and announced Gilead exercised its option to license both HSV programs, including a $35M payment and eligibility for milestones/royalties. by mariel | Dec 9, 2025 | Portfolio News
Ceribell reported > $22M Q3’25 revenue, raised FY25 revenue guidance to $87M–$89M, and received FDA 510(k) clearance for its delirium monitoring solution. by mariel | Dec 8, 2025 | Portfolio News
Mirum announced a definitive agreement to acquire Bluejay and add worldwide rights to brelovitug; Mirum also completed private placements totaling $268M to finance the transaction. by mariel | Nov 7, 2025 | Portfolio News
Vera submitted a BLA via Accelerated Approval for atacicept in IgAN and later reported a PDUFA target action date of July 7, 2026.